glp 1 support groups Everyone’s got an opinion on GLP-1s: your favorite influencer, your group chat, your cousin who read one article. We’re here for the facts, not the noise so you can decide what’s right for you.* GLP1 Support Stack with FREE

Abstract Background Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA)

Iwasaki Y, Sendo M, Dezaki K et al

The semaglutide versus tirzepatide comparison shows tirzepatide achieving 20-22.5% body weight reduction at the highest dose versus 14.9% for semaglutide

Weight loss on these drugs can be significant

Across phase III trials of GLP-1 receptor agonist and multi-hormone receptor modulator obesity drugs in adults with overweight or obesity, the magnitude of blood pressure-lowering was closely associated with the degree of weight loss, highlighting the clinically relevant yet often underappreciated blood pressure-lowering potential of these drugs, the authors concluded

There is no pharmacological difference in absorption based on time of day